Characteristics of nosocomial infection and its effects on the survival of chemotherapy patients with advanced non-small cell lung cancer

Wang,Lili; Li,Yan; Zhang,Xia; Li,Hongxia

doi:10.3892/ol.2017.7144

Characteristics of nosocomial infection and its effects on the survival of chemotherapy patients with advanced non-small cell lung cancer

Authors:
- Lili Wang
- Yan Li
- Xia Zhang
- Hongxia Li
View Affiliations

Affiliations: Department III of Oncology, Binzhou City Central Hospital, Binzhou, Shandong 251700, P.R. China, Department of Hospital Infection-Control, Binzhou City Central Hospital, Binzhou, Shandong 251700, P.R. China, Department of Obstetrics, Binzhou City Central Hospital, Binzhou, Shandong 251700, P.R. China, Department of Senior Cadres, Binzhou City Central Hospital, Binzhou, Shandong 251700, P.R. China
Published online on: October 5, 2017 https://doi.org/10.3892/ol.2017.7144
Pages: 7379-7383
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study was planned to investigate the characteristics of nosocomial infection and its effects on the survival in advanced non-small cell lung cancer (NSCLC) patients. Retrospective analysis was performed for the 169 chemotherapy patients with NSCLC and nosocomial infection during hospitalization in Binzhou City Central Hospital from March, 2013 to January, 2015. In addition, 170 patients without nosocomial infection were also involved as a control group. The distribution of major drug resistance of Gram‑negative (G-) and Gram-positive (G+) were analyzed. The survival conditions of the patients were analyzed according to the nosocomial infection occurrence. The risk factors of nosocomial infection in patients with NSCLC were analyzed by univariate and multivariate logistic analysis. The percentage of G+ infection was 45.6% while G- infection was 54.4%. Nosocomial infections were most common in respiratory system. The median survival time of the observation group was shorter than that of the control group (P<0.05). G- infection was the most common type of infection in nosocomial infection of the patients with NSCLC. The occurrence of infection seriously affected the survival time of patients. Attention is required to the patients older than 60 years undergoing treatment with glucocorticoids as well as immunosuppressive agents.

View Figures

View References

1	Takagi Y, Hosomi Y, Oshita F, Okamoto H, Seki N, Minato K, Aono H, Yamada K, Okuma Y, Hida N, et al: Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced non-small-cell lung cancer: Thoracic Oncology Research Group (TORG) 1014. BMC Cancer. 15:740–750. 2015. View Article : Google Scholar : PubMed/NCBI
2	Kanda S, Horinouchi H, Fujiwara Y, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Kubota K, Tamura T and Ohe Y: Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy. Lung Cancer. 89:287–293. 2015. View Article : Google Scholar : PubMed/NCBI
3	Chen J, Chen J, Ding HY, Pan QS, Hong WD, Xu G, Yu FY and Wang YM: Use of an artificial neural network to construct a model of predicting deep fungal infection in lung cancer patients. Asian Pac J Cancer Prev. 16:5095–5099. 2015. View Article : Google Scholar : PubMed/NCBI
4	Huang BT, Lu JY, Lin PX, Chen JZ, Kuang Y and Chen CZ: Comparison of two RapidArc delivery strategies in stereotactic body radiotherapy of peripheral lung cancer with flattening filter free beams. PLoS One. 10:e01275012015. View Article : Google Scholar : PubMed/NCBI
5	Kubota K, Sakai H, Katakami N, Nishio M, Inoue A, Okamoto H, Isobe H, Kunitoh H, Takiguchi Y, Kobayashi K, et al: Tokyo Cooperative Oncology Group: A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial. Ann Oncol. 26:1401–1408. 2015. View Article : Google Scholar : PubMed/NCBI
6	Zhuang X, Herbert JM, Lodhia P, Bradford J, Turner AM, Newby PM, Thickett D, Naidu U, Blakey D, Barry S, et al: Identification of novel vascular targets in lung cancer. Br J Cancer. 112:485–494. 2015. View Article : Google Scholar : PubMed/NCBI
7	Morichika D, Sato-Hisamoto A, Hotta K, Takata K, Iwaki N, Uchida K, Minami D, Kubo T, Tanimoto M and Kiura K: Fatal Candida septic shock during systemic chemotherapy in lung cancer patient receiving corticosteroid replacement therapy for hypopituitarism: A case report. Jpn J Clin Oncol. 44:501–505. 2014. View Article : Google Scholar : PubMed/NCBI
8	Saito M, Saito W, Kanda A, Ohguro H and Ishida S: A case of paraneoplastic optic neuropathy and outer retinitis positive for autoantibodies against collapsin response mediator protein-5, recoverin, and α-enolase. BMC Ophthalmol. 14:5–10. 2014. View Article : Google Scholar : PubMed/NCBI
9	Gómez MT, Jiménez MF, Aranda JL, Rodríguez M, Novoa NM and Varela G: The risk of bilobectomy compared with lobectomy: A retrospective analysis of a series of matched cases and controls. Eur J Cardiothorac Surg. 46:72–75. 2014. View Article : Google Scholar : PubMed/NCBI
10	Andreas S, Rittmeyer A, Hinterthaner M and Huber RM: Smoking cessation in lung cancer-achievable and effective. Dtsch Arztebl Int. 110:719–724. 2013.PubMed/NCBI
11	Fernández Lorente A, Brooks Acosta S, Vinageras Neninger E, Alvarez Barroso MC, Brito Wilkinson B, Troche Concepción M, Martínez Pérez LB, González Viada CE, Diaz Crespo T and Casacó Parada AR: Effect of blockade of the EGF system on wound healing in patients vaccinated with CIMAvax^® EGF. World J Surg Oncol. 11:2752013. View Article : Google Scholar : PubMed/NCBI
12	Goss GD, O'Callaghan C, Lorimer I, Tsao MS, Masters GA, Jett J, Edelman MJ, Lilenbaum R, Choy H, Khuri F, et al: Gefitinib versus placebo in completely resected non-small-cell lung cancer: Results of the NCIC CTG BR19 study. J Clin Oncol. 31:3320–3326. 2013. View Article : Google Scholar : PubMed/NCBI
13	Huang YH, Terabe M, Pendleton CD, Khursigara Stewart D, Bera TK, Pastan I and Berzofsky JA: Identification and enhancement of HLA-A2.1-restricted CTL epitopes in a new human cancerantigen-POTE. PLoS One. 8:643–665. 2013.
14	Ai Yang SS, Hsu K, Herbert C, Cheng Z, Hunt J, Lewis CR and Thomas PS: Mitochondrial DNA mutations in exhaled breath condensate of patients with lung cancer. Respir Med. 107:911–918. 2013. View Article : Google Scholar : PubMed/NCBI
15	Noro R, Yoshimura A, Yamamoto K, Miyanaga A, Mizutani H, Minegishi Y, Seike M, Kubota K, Kosaihira S, Hino M, et al: East Japan Chesters Group: Alternating chemotherapy with amrubicin plus cisplatin and weekly administration of irinotecan plus cisplatin for extensive-stage small cell lung cancer. Anticancer Res. 33:1117–1123. 2013.PubMed/NCBI
16	Kikuchi R, Isowa N, Tokuyasu H, Kawasaki Y, Onuma H, Miura H, Terada M, Takada T, Gejyo F, Suzuki E, et al: Three cases of resected pleomorphic carcinoma. Ann Thorac Cardiovasc Surg. 16:264–269. 2010.PubMed/NCBI
17	Tanaka J, Tajima S, Ito R, Shimaoka Y, Kuriyama H, Kagamu H, Terada M, Takada T, Gejyo F, Suzuki E, et al: Non-small cell lung carcinoma dying of acute respiratory failure due to aerogenous metastasis. Nihon Kokyuki Gakkai Zasshi. 47:652–657. 2009.(In Japanese). PubMed/NCBI
18	Van Arsdale SA: Chest mass mimicking an implanted port. Clin J Oncol Nurs. 12:673–674. 2008. View Article : Google Scholar : PubMed/NCBI
19	Wampler GL, Ahlgren JD, Lokich JJ, Gullo JJ and Phillips JA: Dichloromethotrexate, infusional cisplatin, and infusional 5-fluorouracil for locally advanced or metastatic non-small cell lung cancer. A MAOP study. Am J Clin Oncol. 14:442–445. 1991. View Article : Google Scholar : PubMed/NCBI
20	Belch AR, Urtasun RC, Bodnar D, Kinney B and Amy R: Use of hemibody irradiation as a non-cross-resistant agent in combination with systematic chemotherapy in small cell lung cancer. NCI Monogr. 11:271–274. 1988.
21	Evans WK, Feld R, Murray N, Pater J, Shelley W, Willan A, Osoba D, Levitt M, Coy P, Hodson I, et al: The use of VP-16 plus cisplatin during induction chemotherapy for small-cell lung cancer. Semin Oncol. 13 Suppl 3:10–16. 1986.PubMed/NCBI